Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.71 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.71 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.71 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.43 |
| ▸ | BLM | P54132 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | LDHA | P00338 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL978830 | 1.00 | GLRA1 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL25330917 | 0.97 | OR51E2 (0.67) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL22518912 | 0.97 | GLRA1 (0.67) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL16600 | 0.93 | GLRA1 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL6237269 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL27455875 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL7078758 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL6237177 | 0.93 | OR51E2 (0.71) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL25331577 | 0.91 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRR1BLM | |
| Glycine SCHEMBL28013371 | 0.91 | GLRA1 (0.59) | GLRA1SLC6A9OR51E2GABRR1BLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332107-A1 | IMMEDIATE RELEASE DOSAGE FORM | KENVUE BRANDS LLC (US) | 2025-10-30 | — | — | US | claimed |
| US-12296049-B2 | Immediate release dosage form | KENVUE BRANDS LLC (US) | 2025-05-13 | — | — | US | claimed |
| EP-4473962-A2 | IMMEDIATE RELEASE DOSAGE FORM | Johnson & Johnson Consumer Inc. (US) | 2024-12-11 | — | — | EP | claimed |
| EP-3781136-B1 | IMMEDIATE RELEASE DOSAGE FORM | JOHNSON & JOHNSON CONSUMER INC (US) | 2024-09-25 | — | — | EP | claimed |
| CN-115279878-B | Cleaning composition | 联合利华知识产权控股有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-118217260-A | Enteric coated tablet | 华益泰康药业股份有限公司 | 2024-06-21 | — | — | CN | claimed |
| US-20240180821-A1 | ORALLY DISINTEGRATING FILM COMPOSITION OF KETOROLAC AND A METHOD OF PREPARATION THEREOF | LN LABORATORIES PVT LTD (IN) | 2024-06-06 | — | — | US | claimed |
| CN-117899041-A | Astragaloside effervescent tablet and preparation process and application thereof | 浙江省肿瘤医院 | 2024-04-19 | — | — | CN | claimed |
| US-20230414520-A1 | IMMEDIATE RELEASE DOSAGE FORM | KENVUE BRANDS LLC | 2023-12-28 | — | — | US | claimed |
| CN-115990142-A | Enteric coated tablet for treating colonitis | 华益泰康药业股份有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-0954292-B1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLICHEM SA (LU) | 2003-07-02 | — | — | EP | claimed |
| WO-2002018539-A2 | METHOD FOR ASSAYING THE ACTIVITY OF LYSOSOMAL ENZYMES | LYSOMETRIX CORPORATION (US) | 2002-03-07 | — | — | WO | claimed |
| EP-0954292-A1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLI INDUSTRIA CHIMICA S.p.A. (IT) | 1999-11-10 | — | — | EP | claimed |
| US-5788987-A | TIME-SPECIFIC CONTROLLED RELEASE DOSAGE FORMULATION | POLI INDUSTRIA CHIMICA SPA (IT) | 1998-08-04 | — | — | US | claimed |
| WO-1998032425-A1 | PHARMACEUTICAL FORMULATIONS WITH DELAYED DRUG RELEASE | POLI INDUSTRIA CHIMICA S.P.A. (US) | 1998-07-30 | — | — | WO | claimed |
| US-5681583-A | SUSTAINED RELEASE; THE DISINTEGRATING RATE OF FIRST LAYER IS FASTER THAN THE SECOND LAYER | APR APPLIED PHARMA RESEARCH SA (CH) | 1997-10-28 | — | — | US | claimed |
| EP-0659074-A1 | MULTILAYERED CONTROLLED-RELEASE ORAL SOLID PHARMACEUTICAL FORMS | APR APPLIED PHARMA RESEARCH S.A. (CH) | 1995-06-28 | — | — | EP | claimed |
| WO-1995001781-A1 | MULTILAYERED CONTROLLED-RELEASE ORAL SOLID PHARMACEUTICAL FORMS | APR APPLIED PHARMA RESEARCH SA (CH) | 1995-01-19 | — | — | WO | claimed |
| EP-0363569-A1 | Spontaneously water-dispersible composition particularly suitable for treating the skin | COMPAGNA ITALIANA SALI C.I.S. S.p.A. (IT) | 1990-04-18 | — | — | EP | claimed |
| US-RE29102-E | Contraception agent | MERZ & CO. (DT) | 1977-01-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180821-A1 | ORALLY DISINTEGRATING FILM COMPOSITION OF KETOROLAC AND A METHOD OF PREPARATION THEREOF | SI, TREH, SORD | GLRA1 2607/4885SLC6A9 2225/4885OR51E2 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.